Targeting Dysfunctional CD8+ T Cells via 4-1BB and LAG-3 Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cancer are often insufficient in targeting and restoring the function of dysfunctional tumor antigen-specific CD8+ T cells within the tumor microenvironment, which are crucial for effective anti-tumor responses but are typically inhibited by immune-suppressive mechanisms.
Innovation Solution
The use of specific antibodies or antibody mimetics targeting receptors such as 4-1BB, LAG-3, and other markers like PD-1, TIM-3, OX-40ICOS, TIGIT, and others to restore the functionality of dysfunctional CD8+ T cells, combined with additional immunotherapeutic agents to enhance anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatment methods are used, then general anti-tumor activity is achieved, but dysfunctional tumor antigen-specific CD8+ T cells cannot be effectively targeted or restored
Solution Approach 1:
The patent applies parameter changes by detecting and targeting specific molecular markers (PD-1, LAG-3, 4-1BB, TIM-3, OX-40ICOS, TIGIT) on dysfunctional T cells to differentiate them from functional T cells. This enables selective targeting based on molecular parameter differences, allowing restoration of anti-tumor immunity while sparing normal immune functions.
Solution Approach 2:
The patent uses antibodies or antibody mimetics as intermediaries that specifically bind to receptors on dysfunctional T cells. These intermediary molecules mediate the restoration of T cell function by blocking inhibitory signals or providing co-stimulatory signals, thereby resolving the contradiction between maintaining general anti-tumor activity and specifically restoring dysfunctional T cell responses.
2Reliability
If multiple immunotherapeutic agents are combined to enhance anti-tumor immunity, then treatment effectiveness improves, but treatment complexity increases
Solution Approach 1:
The patent employs a multi-functional approach where a single therapeutic agent can target multiple inhibitory receptors (PD-1, LAG-3, TIM-3, TIGIT) that are co-expressed on dysfunctional T cells. This universal targeting strategy achieves comprehensive restoration of T cell function while simplifying the treatment regimen compared to sequential or combination therapies targeting each receptor separately.
Solution Approach 2:
The patent merges the detection and therapeutic functions into a unified approach by using antibodies or antibody mimetics that can both detect the presence of dysfunctional T cells through marker expression and simultaneously restore their function by blocking inhibitory receptors or providing co-stimulatory signals. This combined approach reduces treatment complexity while maintaining high effectiveness.
Data Source
AI summary
Provided herein are compositions and methods for detecting and/or targeting dysfunctional tumor antigen-specific CD8+ T cells in the tumor microenvironment for diagnostic, therapeutic and/or research applications. In particular, dysfunctional tumor antigen-specific CD8+ T cells are detected and/or targeted via their expression of cell surface receptors described herein, such as 4-1BB,LAG-3, or additional markers that correlate with 4-1BB and LAG-3 expression, such as markers differentially expressed on the surface of the T cells.